Today: 28 January 2026
Subscribe
Browse Category

NASDAQ:AMC News 10 January 2026 - 13 January 2026

AMC stock in focus: New filing flags possible $150 million share sale from Feb. 2 as Citi cuts target

AMC stock in focus: New filing flags possible $150 million share sale from Feb. 2 as Citi cuts target

NEW YORK, January 13, 2026, 05:39 EST — Premarket Shares of AMC Entertainment Holdings Inc are back in focus ahead of Tuesday’s U.S. open, following the company’s announcement of changes to its exchangeable notes that could trigger new share sales starting early February. The filing matters because AMC’s stock is trading under $2, where even slight shifts in supply can…
13 January 2026
···
AMC stock pops 13% on a volume spike as options heat up and a Feb. 2 stock-sale window nears

AMC stock pops 13% on a volume spike as options heat up and a Feb. 2 stock-sale window nears

New York, January 10, 2026, 05:30 ET — Market closed AMC Entertainment Holdings Inc’s shares surged 13.1% to $1.64 on Friday, beating other movie-theater stocks amid heavy volume. About 71.6 million shares changed hands, nearly triple the 50-day average of 22.5 million. Still, AMC remains about 60% below its 52-week high of $4.08. (MarketWatch) Why it matters now: AMC is…
10 January 2026
····

Stock Market Today

  • Insulet (PODD) Stock Valuation Reflects Share Price Weakness and Growth Expectations
    January 28, 2026, 12:31 AM EST. Insulet's stock has declined over recent periods, with a 7% drop in the past week and over 6% year to date. The company, known for insulin delivery technology, faces investor scrutiny over long-term adoption and competitive pressures in diabetes care. A Discounted Cash Flow (DCF) analysis values Insulet at $324.22 per share, suggesting it is about 18.3% undervalued compared to its last closing price of $264.91. However, its price-to-earnings (P/E) ratio stands at 75.69 times, markedly higher than the industry average of 31.67 and peer average of 46.07, indicating high growth expectations but also increased risk perception. Overall, Insulet scores a low 2 out of 6 on valuation checks, reflecting mixed signals for investors assessing its market position and future prospects.
Go toTop